Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

The study assessed the efficacy and safety of topical GT20029 in 180 Chinese adult males with androgenetic alopecia over 12 weeks. Participants were divided into groups receiving either GT20029 (0.5% or 1.0%) or placebo. Results indicated significant increases in target area non-vellus hair count for all GT20029-treated groups, with the 0.5% QD and 1.0% BIW groups showing notable improvement over placebo. Hair width also improved significantly in the 1.0% BIW group. The incidence of adverse events was similar across all groups and mostly mild. The study concluded that GT20029 is effective for hair regrowth with good tolerability, suggesting it as a promising non-hormonal topical alternative for AGA treatment, warranting further research.